Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE

ConclusionsOver 40% of patients with early axSpA achieved sustained remission during 48  weeks of open-label CZP treatment. Additionally, patients across the axSpA spectrum demonstrated substantial improvements in imaging outcomes and quality of life following treatment. No new safety signals were identified.Trial RegistrationNCT02505542.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research